Skip to main content
. 2007 Jun 21;25(33):6176–6190. doi: 10.1016/j.vaccine.2007.06.005

Table 3.

Parasitologycal evidence of Leishmania infection in control and Leishmune® immunotherapy-treated dogs with time

S 6 m 9 m 11 m
15 m
L 6 m 9 m 11 m
15 m
BMh BM PCR BMh Bh Ln l S Ln BMh BM PCR BMh Bh Ln L s Ln
1 4
2 5
3 + 6 D
7 + + D + Nd Nd Nd 11 + + + + +
8 + + + + + + 12
9 + + D 13 + + +
10 + 14 + +
15 + + + + + 16 + D D
17 D D 19 D + + + +
20 D + + + + 22 + +
21 + D D + + + 23 + + + + + + +
25 + + 24
Signs 4 4 7 6 5 1 4 4 5 3 6 3 3 1 3 4
Total 12 12 12 12 12 11 11 11 12 12 12 12 12 12 12 12

The Leishmania infection was confirmed in saline (S) or Leishmune®-treated dogs (L) by hamster's in vivo culture of bone marrow (BMh), blood (Bh) or by Giemsa stained lymph node (Ln) samples and by PCR analysis for Leishmanial DNA in bone marrow (BM PCR). The presence of Leishmania amastigotes was confirmed after dog's autopsy in liver (l), spleen (s) and lymph nodes (Ln) by microscopy analysis of Giemsa stained smears in month 15. D = hamsters that died of clinically and parasitologycally confirmed visceral leishmaniasis. m = months after infection; Nd = not determined.